Designed to complement our orthotopic and xenograft models of cancer, we can now offer qPCR and NGS targeted sequencing panels for lung, prostate and leukaemia models. Designed from internal development studies, combined with selected published research, these panels highlight many of the genes differentially expressed during disease progression and when treated with standards of care.
- Examples Of Commercially Used Oncology Panels compatible with DNA from FFPE samples that cover copy number variants, Insertions-Deletions (indels), Single Nucleotide Polymorphisms (SNPs) and Somatic Variants etc include the AmpliSeq for Illumina Comprehensive Cancer Panel and the Childhood Cancer Panel. Other panels include kinase domains and DNA repair genes.
- Other panels measure T cell diversity and clonal expansion by sequencing T cell receptor (TCR) beta chain rearrangements for a variety of immunology indications, including immune response to chemo- and immune-therapies.
- Panels to quantify the expression of genes involved in tumour immune response and immune-oncology markers.
Epistem fibrosis panels are derived from fibrotic foci in clinical lung, liver, and kidney fibrosis patients. These panels offer a comprehensive range of genetic markers associated with fibrosis.
Inflammatory Bowel Disease Panels
Epistem has combined RNA sequencing analysis from our T-cell transfer models with published research to create proprietary IBD panels for qPCR and NGS. Our panel includes genes differentially expressed in normal IBD and treated models of the disease.
Epistem also offers microbiome sequencing services for the V1-V4 hypervariable regions of the 16s RNA genes, with the option to sequence the V1-9 hypervariable regions upon request. Our sequencing services are suitable for general microbiome assessments, including those of the gut. In addition to our pre-designed panels, we also offer custom-designed panels for those requiring specific targets.
Our hair biomarker platform has been extensively studied to identify pathways that can be modulated by therapeutics in ex vivo hair cultures, enabling us to develop advanced hair panels for gene expression analysis. These panels are designed to measure gene expression changes in response to drug treatments targeting specific pathways, such as PI3-Kinase inhibitors.